clinical trial · NCT06201559
Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions
GlaxoSmithKline·phase1·completed·n = 70
Intestinal DiseasesAlbendazole IP 400 mgAlbendazole 400 mg
brief summary
The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants. Researchers will compare the extent and rate to which the drug is absorbed.
started
Aug 21, 2023
primary completion
Sep 12, 2023
completion
Sep 12, 2023
last updated
Jan 27, 2025
official title
An Open Label, Balanced, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Full Replicate Crossover, Bioequivalence Study of Albendazole Tablets IP 400 mg of Biddle Sawyer Limited (GSK Group Company) With Albendazole Tablets 400 mg of Glaxo SmithKline Consumer Healthcare, South Africa (PTY) Ltd in Healthy, Adult Participants Under Fed Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol